Data

CLINICAL TRIAL RESULTS SHOW AN INCREASE IN DYSTROPHIN. 1

EXONDYS 51 uses exon skipping to address DMD. Clinical trials confirm the exon-skipping mechanism of action (MoA) of EXONDYS 51.1

 

Review Study Data
*Patient results vary. 
Click to see individual patient data
xavier.png

IS YOUR PATIENT AMENABLE TO EXON 51 SKIPPING?

EXONDYS 51 is for patients with a confirmed genetic mutation that is amenable to exon 51 skipping.1 For exon skipping to work, exon 51 must be present. See the list of common DMD deletions that are amenable to exon 51 skipping.

 

See Exon Deletion List
Logo

GETTING YOUR PATIENTS STARTED.

Through SareptAssist, our patient support program, patients and families get information to help them start and stay on therapy. Get your patients started in just three steps:

  1. Download the START form
  2. Fax it to SareptAssist at 1-800-621-5203
  3. A dedicated SareptAssist Case Manager will contact your patient
Learn About SareptAssist
GET THE LATEST UPDATES FROM SAREPTA.

Sign up for news from Sarepta Therapeutics, including product updates, reimbursement information, and services that may be of interest to you and your patients.

Sign Up

INDICATION

EXONDYS 51 (eteplirsen) is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.

Read More

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions, including bronchospasm, chest pain, cough, tachycardia and urticaria, have occurred in patients who were treated with EXONDYS 51. If a hypersensitivity reaction occurs, institute appropriate medical treatment and consider slowing the infusion or interrupting the EXONDYS 51 therapy.

Adverse reactions in DMD patients (N=8) treated with EXONDYS 51 30 or 50 mg/kg/week by intravenous (IV) infusion with an incidence of at least 25% more than placebo (N=4) (Study 1, 24 weeks) were (EXONDYS 51, placebo): balance disorder (38%, 0%), vomiting (38%, 0%) and contact dermatitis (25%, 0%). The most common adverse reactions were balance disorder and vomiting. Because of the small numbers of patients, these represent crude frequencies that may not reflect the frequencies observed in practice. The 50 mg/kg once weekly dosing regimen of EXONDYS 51 is not recommended.

The most common adverse reactions from observational clinical studies (N=163) seen in greater than 10% of patients were headache, cough, rash, and vomiting.

Please see the full Prescribing Information for EXONDYS 51 (eteplirsen).

 

 

References

  1. EXONDYS 51 [package insert]. Cambridge, MA: Sarepta Therapeutics Inc.
  2. US Food and Drug Administration. FDA grants accelerate approval to first drug for Duchenne muscular dystrophy. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm521263.htm. Published September, 2016. Accessed February 15, 2022.